Decrease (-) Restore Default Increase (+)

Clinical Trials

Topic   Multiple Myeloma
Title   A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment Regimens
Summary   The purpose of this study is to find out if Daratumumab administrated by injection under the skin in combination with standard treatment is effective and safe in patients with newly diagnosed Multiple Myeloma (MM), or with relapsed or refractory disease.
Description   This study has 3 treatment arms. Participants who are newly diagnosed with MM and transplant eligible will receive Daratumumab, bortezomib, lenalidomide, and dexamethasone. Participants who are newly diagnosed MM and transplant ineligible will receive Daratumumab, bortezomib, melphalan, and prednisone. Participants who have relapsed MM will receive Daratumumab, lenalidomide, and dexamethasone.
IRB Number   18010
Inclusion/Notes   To be eligible for this study, patients must meet several criteria, including but not limited to the following: patients must be 18 years of age or older and diagnosed with multiple myeloma.
Status   Open
Start Date   01/26/2018
Principal Name   Marc Braunstein, MD
Contact Name   Ying Lin, RN
Email   Ying.Lin@nyulangone.org
Fax   516-663-1871
Current Trial Type   Interventional
Phone   516-663-4895
Alternate Phone   516-663-3115